RESEARCH MONOGRAPH · KDC-MN-088

IGF-1 DES

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

52/100

Truncated IGF-1 fragment with higher receptor selectivity, useful research tool but limited beyond that

IGF-1 DES (DES(1-3) IGF-1) is a naturally occurring truncated IGF-1 variant lacking the first three N-terminal amino acids (Gly-Pro-Glu), which dramatically reduces IGFBP binding while maintaining IGF-1 receptor agonism. It was originally identified in calf brain and porcine uterus in the 80s by the Ballard and Francis groups in Adelaide, and the truncated form turns out to be 5-10x more potent on a molar basis at the IGF-1R than full-length IGF-1 in IGFBP-rich tissue contexts.

What we like is the structural pharmacology. DES IGF-1 is essentially a built-in solution to the IGFBP-displacement problem that LR3 solves through N-terminal extension, but using truncation instead. As a research tool, it's complementary to LR3 in that the two compounds modify IGFBP affinity through different structural strategies (extension vs. truncation), and comparing them informs IGF-1 receptor pharmacology in IGFBP-replete vs. IGFBP-depleted contexts. The shorter half-life relative to LR3 (closer to 20-30 minutes in serum) is sometimes a feature in studies where pulse-like exposure is desired.

What we dont like: human clinical evidence for DES IGF-1 specifically (as opposed to full-length recombinant IGF-1 or LR3) is essentially absent. The compound has been used in animal models and as a research reagent but never went through serious human development. The hypoglycemia and insulin receptor cross-reactivity concerns apply similarly to LR3, scaled down for the shorter half-life.

Sourcing is at least as bad as LR3 and probably worse. Recombinant production of the truncated variant requires careful processing, and the absence of the N-terminal residues makes it harder to verify identity by some standard analytical methods. Reputable IGF-1 vendors do produce DES variants with adequate analytics, but the cheap-end suppliers are genuinely unreliable. Biological activity assays matter much more than HPLC alone.

For research on IGF-1 receptor pharmacology where IGFBP-independent agonism is desired and shorter half-life is acceptable, DES IGF-1 is a sensible tool. For anything else, this is a narrow research reagent with thin human evidence and the same proliferative-signaling concerns as any IGF-1 receptor agonist. Treat it as the laboratory tool compound it actually is.

Evidence: 40
Mechanism: 75
Reliability: 60
Safety: 45
Sourcing: 48
Value: 50
Signal: 55
Staying power: 45

Plain-language summary Intrigue 58 / 100

IGF-1 DES is a truncated form of IGF-1 missing the first three amino acids. The truncation reduces binding to IGF-binding proteins, producing a more potent local muscle effect. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Truncated IGF-1 analog

A truncated form of IGF-1 missing the first three residues, with reduced IGFBP binding and increased local potency.

Abstract

IGF-1 DES (DES(1-3) IGF-1) is a truncated analog of human IGF-1 missing the first three N-terminal residues (Gly-Pro-Glu). The truncation reduces binding to IGF binding proteins (IGFBPs) and increases the free fraction of the peptide at target tissues, producing approximately 10-fold higher local potency than native IGF-1 at equivalent doses. The compound is sold as a research chemical. Plasma half-life is shorter than IGF-1 LR3 (approximately 20 to 30 minutes for IGF-1 DES vs hours for LR3) due to the absence of the Arg3 modification, but the increased local activity provides higher peak effects per dose. Investigational doses range widely; safety considerations parallel IGF-1 LR3 (chronic IGF-1 elevation effects on cancer risk and acromegalic features).

Mechanism of action

Truncated IGF-1 with reduced IGFBP binding; higher local potency than native IGF-1.

Reported research dose ranges

20 to 100 micrograms SC (reported research dose ranges in the literature).

References

Bagley CJ, et al. Pharmacology of truncated IGF-1 analogs. Biochem J 1989.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-088

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

IGF-1 DES

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs